Phase II trial of carboplatin and etoposide in metastatic breast cancer
Fetal Growth Retardation
Image Interpretation, Computer-Assisted
Infant, Small for Gestational Age
The activity observed with this regimen in patients with no prior chemotherapy coupled with its potential for dose escalation suggests a possible role in high-dose programs with hematopoietic support. The inactivity of the combination in patients with prior therapy for metastatic breast cancer indicates that there is no advantage to its use in the salvage setting.